Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genentech/Novartis Xolair Indication Narrowed To Adult Allergic Asthma

Executive Summary

Genentech and Novartis will seek a narrower label for the asthma biologic Xolair following the receipt of a "complete response" letter from FDA July 5.

You may also be interested in...



Xolair Allergic Asthma Population Should Not Be Restricted Except By Age

Genentech/Novartis' Xolair allergic asthma patient population should not be restricted except by age, FDA's Pulmonary-Allergy Drugs Advisory Committee recommended May 15

Xolair Allergic Asthma Population Should Not Be Restricted Except By Age

Genentech/Novartis' Xolair allergic asthma patient population should not be restricted except by age, FDA's Pulmonary-Allergy Drugs Advisory Committee recommended May 15

Genentech/OSI Tarceva Lung Cancer Trial Modified Following “Safety Signal”

A "safety signal" detected during Genentech's Phase III trial of Tarceva (erlotinib) for first-line combination therapy in non-small cell lung cancer will not impact the rest of the agent's development program, the company said April 9

Related Content

UsernamePublicRestriction

Register

OM014079

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel